aTyr Pharma ATYR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$74.12M-15.8% | -$64.02M-27.0% | -$50.4M-11.1% | -$45.34M-34.2% | ||
| $664K-6.2% | $708K+19.6% | $592K+155% | $232K-51.2% | ||
| $5M+67.2% | $2.99M+15.0% | $2.6M+20.7% | $2.15M+33.5% | ||
| -$33K— | —— | —— | $6.74M+14,243% | ||
| -$8.05M— | —— | -$622K— | —— | ||
| $889K— | —— | $2.15M+46.9% | $1.46M+76.5% | ||
| -$711K— | —— | —— | $2.11M+345% | ||
| —— | —— | —— | $11.92M— | ||
| -$61.99M+10.3% | -$69.12M-108% | -$33.22M+20.7% | -$41.89M-26.6% | ||
| $77K+18.5% | $65K-98.5% | $4.22M+157% | $1.64M+755% | ||
| $93.45M+35.2% | $69.1M-35.4% | $106.98M+154% | $42.12M-66.7% | ||
| $88.46M+2.4% | $86.39M-5.1% | $91.05M+0.2% | $90.83M+159% | ||
| —— | —— | —— | $47.25M+152% | ||
| —— | $0— | $0— | —— | ||
| $539K+8.5% | $497K+26.1% | $394K+497% | $66K— | ||
| $66.14M+65.5% | $39.97M-39.7% | $66.23M+1,115% | $5.45M-95.0% | ||
| —— | —— | —— | —— | ||
| $94K-31.4% | $137K-20.3% | $172K+219% | $54K— | ||
| $1.85M-31.5% | $2.71M-14.7% | $3.17M+661% | -$565K-54.4% | ||
| $5M+67.2% | $2.99M+15.0% | $2.6M+20.7% | $2.15M+33.5% | ||
| -$711K— | —— | —— | $2.11M+345% | ||
| —— | —— | —— | $11.92M— | ||
| -$8.05M— | —— | -$622K— | —— | ||
| $889K— | —— | $2.15M+46.9% | $1.46M+76.5% | ||
| $88.46M+2.4% | $86.39M-5.1% | $91.05M+0.2% | $90.83M+159% | ||
| $539K+8.5% | $497K+26.1% | $394K+497% | $66K— | ||
| $66.44M+65.0% | $40.26M— | —— | $5.47M— | ||
| —— | $0— | $0— | —— | ||
| -$711K— | —— | —— | $2.11M+345% | ||
| $0— | $0-100% | $1.97M-77.3% | $8.7M— | ||
| —— | —— | —— | $1.19M— | ||
| -$62.06M+10.3% | -$69.18M-84.8% | -$37.44M+14.0% | -$43.53M-30.8% | ||
| -$62.06M+10.3% | -$69.18M-84.8% | -$37.44M+14.0% | -$43.53M-30.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does aTyr Pharma generate?
- aTyr Pharma (ATYR) generated -$59.1M in operating cash flow over the trailing twelve months.
- What is aTyr Pharma's free cash flow?
- After $215.0K of capital expenditures, aTyr Pharma's free cash flow was -$59.3M over the trailing twelve months, up 4.7% year over year.
- Where does aTyr Pharma's cash flow data come from?
- Every line is extracted from aTyr Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
